NEWS & INSIGHTS

In January, the Alliance for Regenerative Medicine (ARM) released its State of the Industry Briefing which highlighted a record-breaking year for 2021. $23.1B raised for the advanced medicines sector (a 16% increase from 2020), 2,261 ongoing regenerative medicine clinical trials globally, and the evolution from treating and curing rare monogenetic diseases to more prevalent indications. Could we see 10-20 approvals each year by 2025?

(more…)

A number of legislative events are shaping the managed care landscape in 2022. These events range from broad reaching initiatives outlined in Biden’s Build Back Better Framework to proposals for promoting adoption of biosimilars to Medicare’s Advance Notice for the 2023 benefit year and discussions around Part D re-design as well as others.

(more…)

Attending World EPA Congress March 22-24 in Amsterdam? Don’t miss PRECISIONadvisors Richard Macaulay and David Carr present “Gene Therapies Market Access: Lessons From The Past, Future Best Practice” March 23 at 11:45 CET, and be sure to stop by our booth to speak with one of our experts.

(more…)

Precision will be at this year’s Gene Therapy for Rare Disorders from March 7 – 10^th in Boston. Connect with our team of experts as they lead meaningful presentations and discussions throughout this event providing insights into the clinical development, manufacturing, and commercialization of therapies for rare genetic disorders.

(more…)

As we emerge from another surge in coronavirus cases, there is good reason to believe we are starting 2022 in a better position than we were this time last year.  Yet uncertainty remains. COVID-19 will have a lasting effect on healthcare budgets, as well as in areas such as clinical trials, regulatory processes and reimbursement timelines. At the same time, we are at the cusp of another wave of innovation, with a raft of new treatment modalities due to launch in the coming 12 months.

(more…)

Are you involved in preparing health technology assessment (HTA) submissions and in early health economic modeling as part of drug development decision-making? You won’t want to miss our webinar, “Cost-Effectiveness Analysis with R? A Discussion.” Learn about the pros and cons of R versus Excel in preparing HTA submissions, and the acceptability of R by HTA agencies.

(more…)

Attending Virtual ISPOR EU 2021 30 November-3 December? PRECISIONadvisors and PRECISIONheor will be attending with 18 insightful posters, panels, presentations and workshops!

(more…)

PRECISIONvalue’s 2021 Care Management Survey found that Oncology was the top condition for which patients were referred for Care Management, and tools, resources and programs for supporting medication adherence were the top type of support that respondents would like to receive from pharmaceutical manufacturers.

(more…)

In 2021, PRECISIONvalue launched a proprietary survey of the care management ecosystem (including payers and health systems) and found diabetes to be one of the top conditions for which individuals are referred for care management.

(more…)

Join us on October 26th at 12:00pm EDT for a new Precision webinar in partnership with MedStar Health, a nationally-recognized leader in the integration and application of real world data analytics.

(more…)